Strengths and prices
| Strength | Price per vial | Availability | Batch | |
|---|---|---|---|---|
| 10 mg | $20.00 | In stock | AM-2607-0097 | |
| 50 mg | $30.00 | In stock | AM-2607-0097 |
Every vial carries its batch code and a QR that opens the certificate of analysis for that exact batch. No account is needed to read one.
What it is
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small molecule, not a peptide. It is a membrane-permeable inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT).
Identity
| Type | Small molecule (quinolinium salt) |
|---|---|
| Molecular formula | C10H11N2+ (cation) |
| Molecular weight | 159.21 g/mol (cation) |
| CAS number | 685079-15-6 (cation) |
| PubChem CID | 950107 |
5-Amino-1MQ (5-amino-1-methylquinolinium; IUPAC name 1-methylquinolin-1-ium-5-amine) is a small molecule, not a peptide: a quinoline ring with a methyl group on the ring nitrogen, which carries a permanent positive charge, and an amino group at position 5. The cation has the molecular formula C10H11N2+ and a molecular weight of 159.21 g/mol (PubChem CID 950107, CAS 685079-15-6). Because the charge is permanent, the compound exists as a salt, and the counterion adds to the weight of the solid; the figures here are for the cation alone. Mass spectrometry confirms the identity of the cation and HPLC against a reference standard reports purity. It is supplied as a dry powder in a sealed vial.
What the published research covers
NNMT inhibition by this compound was described in 2018 in cultured fat cells and in diet-induced obese mice. The published work is preclinical; no human trial has been published.
5-Amino-1MQ came out of a medicinal chemistry program at the University of Texas Medical Branch in Galveston that set out to find inhibitors of nicotinamide N-methyltransferase (NNMT), a cytosolic enzyme that transfers a methyl group from S-adenosylmethionine (SAM) to nicotinamide. In a 2017 structure-activity study the group screened N-methylated quinolinium, isoquinolinium, pyridinium and benzimidazolium or benzothiazolium analogues and identified the quinoliniums as the most promising scaffold, with half-maximal inhibition near 1 micromolar; computer docking placed them in the enzyme's nicotinamide-binding site (Neelakantan, 2017).
A 2018 study characterized the series further. The methylquinolinium analogues crossed membranes in permeability assays and did not inhibit related SAM-dependent methyltransferases or enzymes of the NAD+ salvage pathway. In cultured adipocytes the inhibitors lowered the reaction product 1-methylnicotinamide, raised intracellular NAD+ and SAM, and suppressed lipogenesis. In diet-induced obese mice, 5-amino-1MQ reduced body weight, white adipose mass and adipocyte size and lowered plasma total cholesterol, with no change in food intake (Neelakantan, 2018). In 24-month-old mice with an acute muscle injury, the same compound was associated with more muscle stem cell proliferation and fusion, regenerating fibers with nearly twice the cross-sectional area, and peak torque about 70% higher than in controls (Neelakantan, 2019). A 2021 study validated an LC-MS/MS assay for the compound in rat plasma and urine and reported an oral bioavailability of 38.4% in rats (Awosemo, 2021). In a 2024 study, diet-induced obese mice given the compound daily for 28 days gained less body weight and fat mass than controls and showed better glucose tolerance and insulin sensitivity and less hepatic steatosis (Babula, 2024).
All of this work is preclinical, in cell culture, mice and rats, and nearly all of it comes from one research group: the senior author on every paper cited here founded Ridgeline Therapeutics, a company developing NNMT inhibitors, and the later papers declare that interest. No human trial of 5-amino-1MQ has been published, and results in diet-induced obese and aged mice do not establish what the compound does in other species.
Regulatory status
Not approved by the FDA for any use. Supplied for laboratory research only.
Testing and documentation
This is a small molecule, not a peptide: identity is confirmed by mass spectrometry and purity by HPLC against a reference standard. The certificate of analysis for the batch is reachable from the code on the vial.
Questions laboratories ask
- What strengths is 5-Amino-1MQ offered in?
- Vials of 10 mg and 50 mg, as listed on the product page. The amount is on the vial label and on the certificate of analysis for the batch.
- Is 5-Amino-1MQ a peptide?
- No. It is a small molecule, a methylated quinolinium salt. It is listed alongside the peptides because it is tested and documented the same way: identity by mass spectrometry and purity by HPLC against a reference standard.
- Why is the molecular weight given for the cation?
- Because the compound is a salt and the counterion varies by supplier. The figure of 159.21 g/mol is for the 5-amino-1-methylquinolinium cation alone; the salt form of a batch is stated on its certificate of analysis.
- How is a batch tested?
- By an independent laboratory: identity by mass spectrometry and purity by HPLC against a reference standard. The QR code on the vial opens the certificate of analysis for that exact batch; no account is needed to read it.
- Who can order, and how does it ship?
- Orders are accepted under the Research Use Agreement, reaffirmed with every order. Orders ship from Montana, the next business day when paid by card, to United States addresses only and not to freight forwarders.
References
- Neelakantan H et al. (2017). Structure-Activity Relationship for Small Molecule Inhibitors of Nicotinamide N-Methyltransferase. Journal of Medicinal Chemistry. PubMed 28548833
- Neelakantan H et al. (2018). Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochemical Pharmacology. PubMed 29155147
- Neelakantan H et al. (2019). Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle. Biochemical Pharmacology. PubMed 30753815
- Awosemo O et al. (2021). Development & validation of LC-MS/MS assay for 5-amino-1-methyl quinolinium in rat plasma: Application to pharmacokinetic and oral bioavailability studies. Journal of Pharmaceutical and Biomedical Analysis. PubMed 34304009
- Babula JJ et al. (2024). Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction. Diabetes, Obesity & Metabolism. PubMed 39161060
How it ships
Ordering
Ordering needs an account. A retail account opens as soon as you request it and costs nothing. You pay by card at checkout, or by invoice before the order ships. A wholesale account is reviewed before it opens.
Research use only
This product is a research chemical sold solely for in-vitro laboratory research by qualified persons. It is not a drug, food, supplement or cosmetic, has not been evaluated by the FDA, and must not be administered to any person or animal. Read the full agreement